Ablynx annouces a novel preclinical development candidate targeting IL6R

30-Jun-2009 - Belgium

Ablynx announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.

ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target.

According to the company, the low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances